Check out our latest whitepaper on Digital Transformations and learn how you can apply these technologies to improve your own drug discovery process. aspenbiosciences.com/whitepapers/...

Despite all of the uncertainty in the industry, those two elements continue to be a high priority for investors. They want to know how you're going to get the rest of your pipeline across the finish the line in the most capital efficient manner possible.

The past couple of years have been challenging for biotech companies. At #JPM2025, investors were looking for two things: Phase II results, and a #DigitalTransformation story that showed how #AI, #automation and advanced analytics would be used to advance early stage programs into the clinic.

The race for funding is real, but chaos isn't a plan. It's time to swap out the monkeys for a real digital transformation roadmap.

aspenbiosciences.com/whitepapers/...

This is the new reality of drug discovery. What are your six impossible things?

For scientists, it’s :

- Planning new discovery programs

- Coordinating work with scientists across multiple labs and CROs

- Running synthesis requests and assays

- Generating, collecting, and analyzing all the data

...and then doing it all over again.

Watch the video on our YouTube channel for a brief preview.
youtu.be/6fPV1bIttnA?...

Our latest whitepaper contains case studies, examples and implementation strategies that you can apply to improve your drug discovery operations. aspenbiosciences.com/whitepapers/...